Partnerships for Development of Vaccines to Prevent Mycobacterium tuberculosis Infection and/or Disease (R01 Clinical Trial Not Allowed)
This funding opportunity supports researchers working on promising tuberculosis (TB) vaccines before they reach human testing. It will fund preclinical research to develop and advance lead vaccine candidates that prevent Mycobacterium tuberculosis (Mtb) infection and/or TB disease. The goal is to move more strong vaccine candidates into the clinical trial pipeline.
The purpose of this notice of funding opportunity (NOFO) is to solicit research applications focused on preclinical development of lead candidate vaccines to prevent Mycobacterium tuberculosis (Mtb) infection and/or tuberculosis, and to increase the clinical pipeline of viable vaccine candidates…
Source
Awards & funding
Eligibility
Other Eligible Applicants include the following: Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizatio…
Tags
Supporting links
Documents
Similar opportunities
-
Tuberculosis Research Units (P01 Clinical Trial Optional)
-
Rational Design of Vaccines Against Hepatitis C Virus (U19 Clinical Trial Not Allowed)
-
Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed)
-
Notice of Special Interest (NOSI): Accelerating Malaria Vaccine and Monoclonal Antibody Discovery
-
Expanding the Target Landscape by Drugging the Undruggable (R21 Clinical Trial Not Allowed)